Kilitch Drugs (India) Ltd (KILITCH) is currently trading at 185.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kilitch Drugs (India) Limited (KDIL) is a leading pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical formulations in various dosage forms across the globe. KDIL has a strong presence in injectables and is one of the largest manufacturers of cephalosporins in Africa, with manufacturing units in India and Ethiopia. The company's historical growth includes strategic international partnerships and expansions, notably in Yemen and Latin America, to enhance its manufacturing and distribution capabilities. KDIL's product portfolio includes sterile dosages, nutraceuticals, cosmetics, and medical devices, catering to both chronic and acute treatments. Despite the sale of its Paonta Sahib unit, KDIL retains core assets and trademarks, continuing to operate from Mumbai with strategic product partnerships and transfers.

Over the past 52 weeks, Kilitch Drugs (India) Ltd has traded between a low of ₹121.10 and a high of ₹219.68. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kilitch Drugs (India) Ltd has a market capitalization of approximately 643.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kilitch Drugs (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 643.82 Cr, Kilitch Drugs (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kilitch Drugs (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kilitch Drugs (India) Ltd is 22.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.